A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms HOPEFUL-1
- Sponsors Abbott Japan; Eisai Co Ltd
- 10 Jun 2017 Biomarkers information updated
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 11 Jan 2013 Primary endpoint 'Total-Sharp-score' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History